704 related articles for article (PubMed ID: 17949787)
21. [Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx].
Zhao EM; Han DM; Yu ZK; Fan EZ; Li Y
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Feb; 38(1):39-42. PubMed ID: 12778766
[TBL] [Abstract][Full Text] [Related]
22. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
Schmalfeldt B; Prechtel D; Härting K; Späthe K; Rutke S; Konik E; Fridman R; Berger U; Schmitt M; Kuhn W; Lengyel E
Clin Cancer Res; 2001 Aug; 7(8):2396-404. PubMed ID: 11489818
[TBL] [Abstract][Full Text] [Related]
23. Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee.
Chu SC; Yang SF; Lue KH; Hsieh YS; Hsiao TY; Lu KH
J Rheumatol; 2006 Feb; 33(2):311-7. PubMed ID: 16465663
[TBL] [Abstract][Full Text] [Related]
24. Identification of markers of possible prognostic value in 57 giant cell tumors of bone.
Gamberi G; Serra M; Ragazzini P; Magagnoli G; Pazzaglia L; Ponticelli F; Ferrari C; Zanasi M; Bertoni F; Picci P; Benassi MS
Oncol Rep; 2003; 10(2):351-6. PubMed ID: 12579271
[TBL] [Abstract][Full Text] [Related]
25. Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells.
Rosenthal EL; Johnson TM; Allen ED; Apel IJ; Punturieri A; Weiss SJ
Cancer Res; 1998 Nov; 58(22):5221-30. PubMed ID: 9823336
[TBL] [Abstract][Full Text] [Related]
26. Short chain fatty acids inhibit human (SW1116) colon cancer cell invasion by reducing urokinase plasminogen activator activity and stimulating TIMP-1 and TIMP-2 activities, rather than via MMP modulation.
Emenaker NJ; Basson MD
J Surg Res; 1998 Apr; 76(1):41-6. PubMed ID: 9695737
[TBL] [Abstract][Full Text] [Related]
27. Effect of compressive force on the expression of MMPs, PAs, and their inhibitors in osteoblastic Saos-2 cells.
Mitsui N; Suzuki N; Koyama Y; Yanagisawa M; Otsuka K; Shimizu N; Maeno M
Life Sci; 2006 Jul; 79(6):575-83. PubMed ID: 16516240
[TBL] [Abstract][Full Text] [Related]
28. Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.
Steiner E; Pollow K; Hasenclever D; Schormann W; Hermes M; Schmidt M; Puhl A; Brulport M; Bauer A; Petry IB; Koelbl H; Hengstler JG
Gynecol Oncol; 2008 Mar; 108(3):569-76. PubMed ID: 18222533
[TBL] [Abstract][Full Text] [Related]
29. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
[TBL] [Abstract][Full Text] [Related]
30. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
31. Serum cathepsin B and plasma urokinase-type plasminogen activator levels in gastrointestinal tract cancers.
Herszényi L; István G; Cardin R; De Paoli M; Plebani M; Tulassay Z; Farinati F
Eur J Cancer Prev; 2008 Oct; 17(5):438-45. PubMed ID: 18714186
[TBL] [Abstract][Full Text] [Related]
32. Flavonoids inhibit VEGF/bFGF-induced angiogenesis in vitro by inhibiting the matrix-degrading proteases.
Kim MH
J Cell Biochem; 2003 Jun; 89(3):529-38. PubMed ID: 12761886
[TBL] [Abstract][Full Text] [Related]
33. Regulation of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) by bone resorptive factors in osteoblastic cells.
Uchida M; Shima M; Shimoaka T; Fujieda A; Obara K; Suzuki H; Nagai Y; Ikeda T; Yamato H; Kawaguchi H
J Cell Physiol; 2000 Nov; 185(2):207-14. PubMed ID: 11025442
[TBL] [Abstract][Full Text] [Related]
34. Actinobacillus actinomycetemcomitans lipopolysaccharide regulates matrix metalloproteinase, tissue inhibitors of matrix metalloproteinase, and plasminogen activator production by human gingival fibroblasts: a potential role in connective tissue destruction.
Bodet C; Andrian E; Tanabe S; Grenier D
J Cell Physiol; 2007 Jul; 212(1):189-94. PubMed ID: 17299802
[TBL] [Abstract][Full Text] [Related]
35. [Significance in gene expression of matrix metalloproteinase-9, urokinase-type plasminogen activator and tissue inhibitor of metalloproteinase for metastases of gastric and/or colo-rectal cancer].
Koumura H; Sugiyama Y; Kunieda K; Saji S
Gan To Kagaku Ryoho; 1997 Jul; 24 Suppl 2():324-31. PubMed ID: 9263524
[TBL] [Abstract][Full Text] [Related]
36. Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma.
Inuzuka K; Ogata Y; Nagase H; Shirouzu K
J Surg Res; 2000 Oct; 93(2):211-8. PubMed ID: 11027463
[TBL] [Abstract][Full Text] [Related]
37. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
Duffy MJ; Duggan C
Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235
[TBL] [Abstract][Full Text] [Related]
38. Expression of matrix metalloproteinases, tissue inhibitors of metalloproteinase, collagens, and Ki67 antigen in pleural malignant mesothelioma: an immunohistochemical and electron microscopic study.
Hirano H; Tsuji M; Kizaki T; Sashikata T; Yoshi Y; Okada Y; Mori H
Med Electron Microsc; 2002 Mar; 35(1):16-23. PubMed ID: 12111403
[TBL] [Abstract][Full Text] [Related]
39. Urokinase-type plasminogen activator and metalloproteinase-2 are independently related to the carotid atherosclerosis in haemodialysis patients.
Pawlak K; Pawlak D; Myśliwiec M
Thromb Res; 2008; 121(4):543-8. PubMed ID: 17706748
[TBL] [Abstract][Full Text] [Related]
40. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.
Wang L; Madigan MC; Chen H; Liu F; Patterson KI; Beretov J; O'Brien PM; Li Y
Gynecol Oncol; 2009 Aug; 114(2):265-72. PubMed ID: 19450871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
